{"id":"modified-release-hydrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocortisone is a glucocorticoid that binds to glucocorticoid receptors in the cytoplasm and nucleus, modulating gene expression to produce anti-inflammatory and immunosuppressive effects. The modified release formulation extends drug delivery over time, allowing for more physiologic cortisol replacement patterns compared to immediate-release formulations, particularly beneficial in adrenal insufficiency where maintaining appropriate circulating cortisol levels throughout the day is critical.","oneSentence":"Modified release hydrocortisone provides sustained glucocorticoid replacement by delivering hydrocortisone in a controlled manner to mimic the body's natural cortisol rhythm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:41.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adrenal insufficiency (primary and secondary)"},{"name":"Congenital adrenal hyperplasia"}]},"trialDetails":[{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT05299554","phase":"PHASE3","title":"Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-04-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":76},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT05063994","phase":"PHASE3","title":"Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-05-24","conditions":"Congenital Adrenal Hyperplasia","enrollment":55},{"nctId":"NCT03062280","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-08-18","conditions":"Congenital Adrenal Hyperplasia","enrollment":91},{"nctId":"NCT01661387","phase":"","title":"A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)","status":"TERMINATED","sponsor":"Shire","startDate":"2012-08-07","conditions":"Chronic Adrenal Insufficiency","enrollment":3258},{"nctId":"NCT05468372","phase":"PHASE2","title":"Amphotericin Versus Posaconazole for Pulmonary Mucormycosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-07-01","conditions":"Mucormycosis; Pulmonary (Etiology)","enrollment":50},{"nctId":"NCT06275490","phase":"NA","title":"Post Extraction Changes Following Ridge Preservation Using Partially Demineralized Dentin Block Versus L- PRF Block","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2024-01-01","conditions":"Socket Preservation","enrollment":20},{"nctId":"NCT05222152","phase":"PHASE2","title":"Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2021-11-23","conditions":"Primary Adrenal Insufficiency","enrollment":58},{"nctId":"NCT02408068","phase":"PHASE1","title":"Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2015-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT00519818","phase":"PHASE1, PHASE2","title":"Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2007-08","conditions":"Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome","enrollment":20},{"nctId":"NCT03532022","phase":"PHASE3","title":"Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy","status":"WITHDRAWN","sponsor":"Neurocrine UK Limited","startDate":"2018-10-04","conditions":"Congenital Adrenal Hyperplasia","enrollment":""},{"nctId":"NCT03013166","phase":"","title":"THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone","status":"COMPLETED","sponsor":"Shire","startDate":"2016-09-01","conditions":"Adrenal Insufficiency","enrollment":3000},{"nctId":"NCT02716818","phase":"PHASE3","title":"Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-02-22","conditions":"Congenital Adrenal Hyperplasia","enrollment":122},{"nctId":"NCT00915343","phase":"PHASE2, PHASE3","title":"Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency","status":"COMPLETED","sponsor":"Shire","startDate":"2007-08-21","conditions":"Adrenal Insufficiency","enrollment":64},{"nctId":"NCT03499379","phase":"","title":"Stress Hormones and IUDs","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-04-16","conditions":"Contraception, Mood Change","enrollment":39},{"nctId":"NCT02277587","phase":"PHASE4","title":"Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2014-03","conditions":"Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency","enrollment":89},{"nctId":"NCT03282487","phase":"PHASE4","title":"Optimising Steroid Replacement in Patients With Adrenal Insufficiency","status":"UNKNOWN","sponsor":"The Adelaide and Meath Hospital, incorporating The National Children's Hospital","startDate":"2017-09-05","conditions":"Adrenal Insufficiency","enrollment":60},{"nctId":"NCT01735617","phase":"PHASE2","title":"Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2012-12","conditions":"Endocrine Disease, Adrenal Insufficiency, Congenital Adrenal Hyperplasia","enrollment":16},{"nctId":"NCT02282150","phase":"PHASE4","title":"Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism","status":"UNKNOWN","sponsor":"Ulla Feldt-Rasmussen","startDate":"2016-10","conditions":"Adrenal Insufficiency","enrollment":30},{"nctId":"NCT03019614","phase":"PHASE1","title":"An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2010-03","conditions":"Congenital Adrenal Hyperplasia, Adrenal Insufficiency","enrollment":30},{"nctId":"NCT02915380","phase":"","title":"Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage","status":"UNKNOWN","sponsor":"Dr. Rita Bertuetti","startDate":"2017-01","conditions":"Thyroid Disfunction, Subarachnoid Haemorrhage From Cerebral Aneurism Rupture, Pituitary Disfunction","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plenadren"],"phase":"marketed","status":"active","brandName":"Modified release hydrocortisone","genericName":"Modified release hydrocortisone","companyName":"The Adelaide and Meath Hospital, incorporating The National Children's Hospital","companyId":"the-adelaide-and-meath-hospital-incorporating-the-national-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Modified release hydrocortisone provides sustained glucocorticoid replacement by delivering hydrocortisone in a controlled manner to mimic the body's natural cortisol rhythm. Used for Adrenal insufficiency (primary and secondary), Congenital adrenal hyperplasia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}